{"title": "Hypothesis: Age‑dependent shift in enteric glial metabolism drives cholinergic neuron loss via suppressed ketone‑body signaling", "body": "# Hypothesis\n\nCore claim – In the aging myenteric plexus, enteric glia undergo a metabolic reprogramming that reduces ketone‑body production and signaling, which in turn diminishes trophic support for cholinergic neurons and accelerates their loss. This glial metabolic shift is an active, conserved response to rising oxidative and inflammatory stress, not a passive byproduct of damage accumulation.\n\n## Mechanistic rationale\n\n1. Glial metabolic flexibility – Enteric glia can switch between glycolysis and oxidative phosphorylation, and they produce ketone bodies (β‑hydroxybutyrate, BHB) from fatty acids when glucose is limited. BHB acts as a signaling molecule through the hydroxycarboxylic acid receptor 2 (HCAR2) on glia and neurons, stimulating cAMP/PKA pathways that upregulate BDNF and GDNF secretion.[2]\n2. Age‑related decline in circulating ketones – Serum BHB falls with age in rodents and humans, a trend reversed by caloric restriction (CR) or ketogenic diets.[5] Lower BHB reduces HCAR2 activation in the gut wall.\n3. Glial HCAR2 loss diminishes neuronal support – HCAR2‑dependent glial release of BDNF/GDNF maintains cholinergic phenotype and suppresses pro‑inflammatory microglial activation. When HCAR2 signaling wanes, glia shift toward a reactive, glycolytic state that secretes IL‑1β and TNF‑α, exacerbating oxidative stress on nearby neurons.[3][4]\n4. Feedback loop – Neuronal stress releases ATP and lactate, further pushing glia into glycolysis and suppressing ketogenesis, creating a self‑reinforcing cycle of glial dysfunction and neuronal loss.\n\n## Testable predictions\n\n- Prediction 1: Aged mice (≥24 mo) will show reduced BHB levels in the colonic wall and decreased HCAR2 expression in Sox10⁺ enteric glia compared with young controls.\n- Prediction 2: Chronic administration of a ketone body (e.g., BHB‑ester) or a selective HCAR2 agonist to aged mice will increase glial BDNF/GDNF output, attenuate cholinergic neuron loss (ChAT⁺ myenteric cells), and improve colonic transit measured by bead expulsion.\n- Prediction 3: Genetic deletion of Hcar2 specifically in enteric glia (Sox10‑Cre;Hcar2^fl/fl) will mimic the aged phenotype in young mice, causing accelerated cholinergic neuron decline even under CR conditions.\n- Prediction 4: Blocking glycolysis in glia with 2‑deoxy‑glucose in aged mice will restore ketone production, rescue HCAR2 signaling, and partially restore neuron numbers.\n\n## Falsifiability\n\nIf any of the following occurs, the hypothesis is falsified:\n- BHB supplementation or HCAR2 agonism fails to improve cholinergic neuron survival or motility in aged animals.\n- Glial Hcar2 deletion does not exacerbate neuron loss or does not reproduce the aged phenotype.\n- Measurements show no age‑dependent change in colonic BHB, HCAR2, or glial glycolytic markers.\n\n## Experimental outline\n\n1. Metabolite profiling – LC‑MS of colonic tissue extracts from young (3 mo) and old (24 mo) mice to quantify BHB, acetoacetate, and lactate.\n2. Cell‑type‑specific signaling – Immunofluorescence and qPCR for Hcar2, BDNF, GDNF, and glycolytic enzymes (Hk2, Pfkfb3) in FACS‑sorted Sox10⁺ glia and ChAT⁺ neurons.\n3. Intervention studies – Oral BHB‑ester (1 g/kg/day) or HCAR2 agonist (e.g., nicotinic acid derivative) for 8 weeks; controls receive vehicle.\n4. Functional readouts – Colonic transit using radiopaque beads; immunohistochemistry for ChAT⁺ neuron density; glial activation (GFAP, vimentin).\n5. Genetic validation – Cross Sox10‑CreERT2 with Hcar2^fl/fl; induce deletion at 2 mo and assess phenotype at 12 mo vs. wild‑type littermates.\n\n## Broader implications\n\nConfirming that glial ketone signaling actively sustains enteric cholinergic neurons would reframe age‑related motility decline as a reversible metabolic mismatch rather than inevitable damage. It would suggest that longevity strategies targeting glial metabolism—such as intermittent fasting, ketone esters, or HCAR2 modulators—could preserve gut health by working with an evolutionarily conserved nutrient‑sensing pathway instead of overriding a presumed "program" of decay."}